tetano
Editor, Senior Moderator
J Clin Transl Hepatol
. 2023 Jun 28;11(3):718-735.
doi: 10.14218/JCTH.2022.00339. Epub 2023 Jan 16.
Efficacy of Vaccine Protection Against COVID-19 Virus Infection in Patients with Chronic Liver Diseases
Carmen Ka Man Cheung[SUP] 1 [/SUP], Kimmy Wan Tung Law[SUP] 2 [/SUP], Alvin Wing Hin Law[SUP] 2 [/SUP], Man Fai Law[SUP] 1 [/SUP], Rita Ho[SUP] 3 [/SUP], Sunny Hei Wong[SUP] 4 [/SUP]
Affiliations
Abstract
The outbreak of coronavirus disease 2019 (COVID-19) has resulted in significant morbidity and mortality worldwide. Vaccination against coronavirus disease 2019 is a useful weapon to combat the virus. Patients with chronic liver diseases (CLDs), including compensated or decompensated liver cirrhosis and noncirrhotic diseases, have a decreased immunologic response to coronavirus disease 2019 vaccines. At the same time, they have increased mortality if infected. Current data show a reduction in mortality when patients with chronic liver diseases are vaccinated. A suboptimal vaccine response has been observed in liver transplant recipients, especially those receiving immunosuppressive therapy, so an early booster dose is recommended to achieve a better protective effect. Currently, there are no clinical data comparing the protective efficacy of different vaccines in patients with chronic liver diseases. Patient preference, availability of the vaccine in the country or area, and adverse effect profiles are factors to consider when choosing a vaccine. There have been reports of immune-mediated hepatitis after coronavirus disease 2019 vaccination, and clinicians should be aware of that potential side effect. Most patients who developed hepatitis after vaccination responded well to treatment with prednisolone, but an alternative type of vaccine should be considered for subsequent booster doses. Further prospective studies are required to investigate the duration of immunity and protection against different viral variants in patients with chronic liver diseases or liver transplant recipients, as well as the effect of heterologous vaccination.
Keywords: COVID-19; Chronic liver disease; Liver transplantation; SARS-CoV-2; Vaccine; mRNA.
. 2023 Jun 28;11(3):718-735.
doi: 10.14218/JCTH.2022.00339. Epub 2023 Jan 16.
Efficacy of Vaccine Protection Against COVID-19 Virus Infection in Patients with Chronic Liver Diseases
Carmen Ka Man Cheung[SUP] 1 [/SUP], Kimmy Wan Tung Law[SUP] 2 [/SUP], Alvin Wing Hin Law[SUP] 2 [/SUP], Man Fai Law[SUP] 1 [/SUP], Rita Ho[SUP] 3 [/SUP], Sunny Hei Wong[SUP] 4 [/SUP]
Affiliations
- PMID: 36969905
- PMCID: PMC10037513
- DOI: 10.14218/JCTH.2022.00339
Abstract
The outbreak of coronavirus disease 2019 (COVID-19) has resulted in significant morbidity and mortality worldwide. Vaccination against coronavirus disease 2019 is a useful weapon to combat the virus. Patients with chronic liver diseases (CLDs), including compensated or decompensated liver cirrhosis and noncirrhotic diseases, have a decreased immunologic response to coronavirus disease 2019 vaccines. At the same time, they have increased mortality if infected. Current data show a reduction in mortality when patients with chronic liver diseases are vaccinated. A suboptimal vaccine response has been observed in liver transplant recipients, especially those receiving immunosuppressive therapy, so an early booster dose is recommended to achieve a better protective effect. Currently, there are no clinical data comparing the protective efficacy of different vaccines in patients with chronic liver diseases. Patient preference, availability of the vaccine in the country or area, and adverse effect profiles are factors to consider when choosing a vaccine. There have been reports of immune-mediated hepatitis after coronavirus disease 2019 vaccination, and clinicians should be aware of that potential side effect. Most patients who developed hepatitis after vaccination responded well to treatment with prednisolone, but an alternative type of vaccine should be considered for subsequent booster doses. Further prospective studies are required to investigate the duration of immunity and protection against different viral variants in patients with chronic liver diseases or liver transplant recipients, as well as the effect of heterologous vaccination.
Keywords: COVID-19; Chronic liver disease; Liver transplantation; SARS-CoV-2; Vaccine; mRNA.